Research programme: cyclin-dependent kinase inhibitors - GPC Biotech

Drug Profile

Research programme: cyclin-dependent kinase inhibitors - GPC Biotech

Alternative Names: GPC 285978; GPC 286199; RGB-286199; RGB-344064

Latest Information Update: 13 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GPC Biotech AG
  • Developer Agennix AG
  • Class Pyrazoles; Small molecules
  • Mechanism of Action Cyclin-dependent kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 30 Aug 2007 GPC Biotech slows down certain ongoing activities and no further commitments to be made to its cell-cyle inhibitor programme; development is suspended until further resources are available
  • 02 May 2006 Preclinical trials in Cancer in USA (unspecified route)
  • 21 Jun 2005 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top